Advanced Medical Isotope Corporation Message Board

I could see that happening. Here's sample from a recent article on Market Playground:

And that is where Cargill’s investing in a new and less expensive method to produce quality stevia via a microbial fermentation system comes in. Stevia is expensive, far more expensive than the artificial sweeteners. To grow the stevia plant it requires a large capital investment, not just the plants or seeds, but in land and equipment for growing and harvesting. Then there is the added cost of extracting the sweet steviol glycosides from the leaves. Artificial sweeteners, on the other hand, are comparatively cheap, as the sweetener consists of a blend of inexpensive chemicals. Therefore, one of the challenges that is holding back stevia is the economics of cost. However, by developing a microbial fermentation method, both Cargill and STVF are attempting to make stevia an economically feasible natural zero calorie sugar substitute by lowering the cost to produce stevia by upwards of 70% while securing a constant supply line.

One option is that Cargill could work with STVF--not sure in what capacity a licensing deal could happen--interesting prospect.

Sentiment: Strong Buy

The deal is the company continues to make efforts in moving forward with growing and seed development as we see in the headlines the STVF reaching out to partner up and work together with others, including the FDA. The next big catalyst will most likely be the actual stevia product on store shelves (the "table top" product). But expect to continue seeing partnering up and updates on field trials.

Sentiment: Strong Buy

I feel ya guys. Its certainly a game in patience and waiting. All I can say is that this is a great level to get in on the stock--super affordable. When things do happen and revenue is produced (yes, WHEN...not IF) then the stock will reflect that. The stock was damaged by the major insider selling that happened a few months back...probably some drama there.

Good luck guys.

Sentiment: Strong Buy

Wagner, the company has plans to release a "table top product" already this year. Also, the FDA is wokring with the company. Things are bound to look up...waiting game however.

Sentiment: Buy

Great deal of thumbs down. Lots of haters. There are always those that wish to squelch good things. Galena is a stand out .

Sentiment: Strong Buy

Good piece of news.

Weight loss drugs in general can prove quite lucrative.

I'm afraid a lot of biotech is a waiting game.

WSU Poised to Produce Medical Isotopes for DOE and the Nation

When Washington State University can use its expertise and infrastructure to serve our state, nation, and world, it is important that we do precisely that. Recent developments in medical isotopes research have once again afforded us the opportunity to make a significant and lasting impact on the world around us.

Every year in America, over 25 million medical diagnostic procedures and treatment strategies that rely on the medical isotope molybdenum-99 (Mo-99) are performed. But the supply of this isotope is in jeopardy and our nation faces catastrophic failure of the supply chain. The resulting shortage will put a halt to these invaluable procedures, which involve many cardiac and cancer patients.

Congress has recognized the gravity of this situation, and has charged the Dept of Energy with developing a safe, reliable, and domestic supply of Mo-99 by December 2013. Better still, to help mitigate nuclear threats, the nation needs this demand to be met using low enriched uranium (LEU) fuel sources that cannot be cycled into nuclear weapons.

To achieve congressional and NNSA milestones in a timely manner, WSU has assembled a team of exceptionally qualified individuals from the WSU Dodgen Research Facility and Pacific Northwest National Laboratory (PNNL) to lead this innovative approach to supply Mo-99 for the nation. This team, along with Merrick & Company, and Goodwin Proctor, will undertake a parallel Commercial Scale Demonstration.

Simultaneously, we will complete the necessary Infrastructure Development Plan, which includes the construction of a new medical isotope processing facility and the development of the capacity to extract radionuclides (i.e., Mo-99). Co-location of target irradiation and the Mo-99 extraction process will alleviate the complex security implications and costs associated with shipping irradiated targets.

The Commercial Scale Demonstration involves a conversion phase to include (1) target design, (2) target irradiation, and (3) post-irradiation target processing at a pilot scale followed by the demonstration phase to ensure that the entire process satisfies the necessary standards of quality, purity and reliability required for full scale production. Highly qualified professional service organizations will play a pivotal role in preparing the necessary facility designs and construction, licensing, permitting and regulatory approvals to ensure a successful path to market through commercial vendors.

This proposal has several key attributes that are unique, and position WSU to expeditiously meet the congressional mandate. Quite simply, we have an incredibly safe reactor design with a spotless record. And since we have already converted to LEU fuel, we are well-positioned to meet Congress’s mandate, perhaps faster than any other site in the U.S. Our ability to partner with a national laboratory to refine the separation chemistry also makes us able to meet the nation’s demand for Mo-99 quickly.

Another positive consequence of this project involves the revenue generated from Mo-99 production, which will further the core research mission by generating funds to invest in innovative WSU research and graduate student training. WSU already has a vigorous radiochemistry program with over 20 students seeking their PhDs. As a matter of fact, we graduate more PhDs in nuclear chemistry than any other university. I would like to repeat that--WSU graduates more PhDs in nuclear chemistry than any other university; thus, we are a major contributor to our nation’s security.

This is a big project. But, if it proves successful, WSU will become a model for how intensive and extensive partnerships may be utilized to drive basic research and graduate education while simultaneously making an enormous and positive impact on our state, nation, and world. It will transform and strengthen much of our approach to technology transfer.

In short, WSU and its partners have the expertise, facilities, funding, and management plan to facilitate rapid progress toward a robust commercial supply of this important medical isotope. In the medium- and long-term, this approach represents an enormous opportunity to advance our research and graduate education missions. But it also positions the research university to drive economic development in our region while expanding our technology transfer operation in creative and innovative directions.

Thanks for the post buddy.

Sentiment: Strong Buy

I found the article, thank you. Personally, I think Market playground is a great website. Been doing some reading on there for a while now. And I think that STVF is an investment with risk worth taking. Once the company becomes set up and growing on US soil, it will be unstoppable.

Sentiment: Strong Buy